11/20
08:57 am
apvo
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies [Yahoo! Finance]
Medium
Report
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies [Yahoo! Finance]
11/20
08:35 am
apvo
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Medium
Report
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
11/15
03:08 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/11
08:20 am
apvo
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial [Yahoo! Finance]
Medium
Report
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial [Yahoo! Finance]
11/11
08:05 am
apvo
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
High
Report
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
11/7
08:05 am
apvo
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
High
Report
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
11/7
02:04 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/30
02:07 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/29
08:05 am
apvo
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
High
Report
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
10/24
02:42 am
apvo
Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update [Yahoo! Finance]
Medium
Report
Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update [Yahoo! Finance]
10/22
02:02 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/14
02:18 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/6
08:09 pm
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/27
02:02 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/23
10:02 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) had its price target lowered by analysts at Roth Mkm from $15.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) had its price target lowered by analysts at Roth Mkm from $15.00 to $8.00. They now have a "buy" rating on the stock.
9/19
02:34 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/18
04:05 pm
apvo
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Medium
Report
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
9/16
08:19 pm
apvo
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
High
Report
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
9/16
08:05 pm
apvo
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
High
Report
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
9/16
08:05 am
apvo
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
High
Report
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
9/13
08:39 am
apvo
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 [Yahoo! Finance]
Low
Report
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 [Yahoo! Finance]
9/13
08:05 am
apvo
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
Medium
Report
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
9/11
02:04 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/3
02:07 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
8/26
02:05 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.